Health Canada approves Celltrion's Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
chronic idiopathic urticaria (CIU), allergic asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP) Celltrion expands biosimilar portfolio to address allergic and respiratory diseases, enhancing access to innovative treatments in Canada TORONTO, December 10, 2024 BUSINESS WIRE )--Celltrion today announced that Health Canada has approved Omlyclo ™ , a biosimilar referencing Xolair ® . Omlyclo ™ is approved for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also called chronic spontaneous urticaria (CSU), adult and pediatric patients with allergic asthma, and adults with chronic rhinosinusitis with nasal polyps (CRSwNP). "Diseases such as CIU have substantial detrimental effects on the quality of life for patients, often impacting both their physical and emotional well-being. Over the last two decades, omalizumab has been the only anti-IgE antibody that has been approved for chronic idiopathic urticaria (CIU) and asthma, and there still rem
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Sandoz Boss Warns There's a Climate Cost of Obesity Wonder Drugs [Yahoo! Finance]Yahoo! Finance
- Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- NVS vs. LLY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 11/25/24 - Form 6-K
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- NVS's page on the SEC website